ModernMedicine Resource Center More Topics

Bladder Cancer Resource Center

Chemo instillation reduces bladder Ca recurrenceFor suspected low-grade, newly diagnosed, or occasionally recurrent bladder cancer, a single post-transurethral resection of bladder tumor instillation of gemcitabine (Gemzar) reduces bladder cancer recurrence by 47%, according to a recent study.
Physical inactivity raises bladder cancer riskResearchers have observed an association between a lifetime of inactivity and higher risks for bladder and renal cancers.
How do bladder Ca treatments compare in terms of survival?
How do bladder Ca treatments compare in terms of survival?There are no notable differences in overall survival, disease-specific survival, and progression-free survival between radical cystectomy and bladder-preserving combined modality treatment for muscle-invasive bladder cancer, according to a recent meta-analysis.
Software could help prevent post-cystectomy readmissionResearchers have developed software that can generate, in real time, whether a radical cystectomy patient is likely to be rehospitalized and when the urologist should follow up with the patient.
NMIBC guideline compliance remains lowUrologists’ compliance with nonmuscle-invasive bladder cancer guidelines has improved with respect to delivery of perioperative mitomycin, but other care measures continue to be suboptimal, according to a new study.
Chemotherapy may harness immune system in bladder Ca“The immune system may be an under-recognized contributor to the tumor response to chemotherapy,” said researcher Philip H. Abbosh, MD, PhD.
Fluorescent cystoscopy outperforms white light methodA recent study found that compared to white light cystoscopy, fluorescent cystoscopy was linked to a 41% decreased risk of bladder cancer recurrence at less than 3 months.
A new standard of care in muscle-invasive bladder Ca?Chemoradiotherapy is an effective alternative to cystectomy in the primary management of muscle-invasive bladder cancer, British researchers say.
Immunotherapy found efficacious as second-line therapyResults of an international randomized phase III study show that pembrolizumab (Keytruda) as second-line therapy for advanced urothelial carcinoma provided superior overall survival and a better safety profile compared with commonly used chemotherapy options.
Novel bladder Ca agent shows promise in phase II trialAn investigatory bladder cancer agent was associated with a 12-month high-grade recurrence-free survival of 35% for patients with Ta/T1 disease, researchers reported.